NASDAQ:SRPT - Sarepta Therapeutics Stock Price, Price Target & More

$77.61 +1.21 (+1.58 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$76.40
Today's Range$74.51 - $78.17
52-Week Range$28.82 - $84.37
Volume904,533 shs
Average Volume1.50 million shs
Market Capitalization$5.09 billion
P/E Ratio-46.76
Dividend YieldN/A
Beta1.29

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRPT
CUSIPN/A
Phone617-274-4000

Debt

Debt-to-Equity Ratio0.54%
Current Ratio13.91%
Quick Ratio12.96%

Price-To-Earnings

Trailing P/E Ratio-46.76
Forward P/E Ratio-65.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$154.58 million
Price / Sales32.62
Cash FlowN/A
Price / CashN/A
Book Value$12.21 per share
Price / Book6.36

Profitability

EPS (Most Recent Fiscal Year)($1.64)
Net Income$-50,680,000.00
Net Margins-32.79%
Return on Equity-30.59%
Return on Assets-22.85%

Miscellaneous

Employees255
Outstanding Shares64,980,000

How to Become a New Pot Stock Millionaire

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) released its quarterly earnings results on Thursday, March, 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.05. The biotechnology company had revenue of $57.30 million for the quarter, compared to analyst estimates of $57.33 million. Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The firm's revenue for the quarter was up 961.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.71) EPS. View Sarepta Therapeutics' Earnings History.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Sarepta Therapeutics.

What price target have analysts set for SRPT?

19 Wall Street analysts have issued 1-year target prices for Sarepta Therapeutics' shares. Their forecasts range from $55.00 to $101.00. On average, they anticipate Sarepta Therapeutics' share price to reach $82.5906 in the next twelve months. View Analyst Ratings for Sarepta Therapeutics.

What are Wall Street analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
  • 1. According to Zacks Investment Research, "Sarepta's Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year. Loss estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (2/7/2018)
  • 2. Cowen Inc analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)

Who are some of Sarepta Therapeutics' key competitors?

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:
  • Douglas S. Ingram, President, Chief Executive Officer (Age 54)
  • Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer (Age 52)
  • David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary (Age 45)
  • Alexander Cumbo, Senior Vice President, Global Commercial Development (Age 46)
  • Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality (Age 57)
  • Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer (Age 54)
  • Michael W. Bonney, Director (Age 59)
  • Richard J. Barry, Independent Director (Age 58)
  • M. Kathleen Behrens Ph.D., Independent Director (Age 64)
  • Claude Nicaise M.D., Independent Director (Age 64)

Has Sarepta Therapeutics been receiving favorable news coverage?

News stories about SRPT stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.14 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $77.61.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $5.09 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]


MarketBeat Community Rating for Sarepta Therapeutics (SRPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  923 (Vote Outperform)
Underperform Votes:  579 (Vote Underperform)
Total Votes:  1,502
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sarepta Therapeutics (NASDAQ:SRPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Sarepta Therapeutics in the last 12 months. Their average twelve-month price target is $82.5906, suggesting that the stock has a possible upside of 6.42%. The high price target for SRPT is $101.00 and the low price target for SRPT is $55.00. There are currently 2 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.852.852.80
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $82.5906$79.6647$66.5755$65.9474
Price Target Upside: 6.42% upside1.06% downside1.41% upside38.43% upside

Sarepta Therapeutics (NASDAQ:SRPT) Consensus Price Target History

Price Target History for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/23/2018HC WainwrightReiterated RatingBuy$92.00HighView Rating Details
4/5/2018Credit Suisse GroupSet Price TargetBuy$100.00MediumView Rating Details
3/21/2018Morgan StanleyDowngradeOverweight -> Equal Weight$64.00 -> $87.00MediumView Rating Details
3/16/2018SunTrust BanksBoost Price TargetBuy$95.00MediumView Rating Details
3/14/2018Royal Bank of CanadaReiterated RatingBuy$91.00MediumView Rating Details
3/14/2018JPMorgan ChaseBoost Price TargetOverweight -> Overweight$75.00 -> $95.00LowView Rating Details
3/13/2018Leerink SwannReiterated RatingOutperform -> Positive$79.00 -> $92.00MediumView Rating Details
3/12/2018Piper JaffrayReiterated RatingOverweight$83.00 -> $76.12HighView Rating Details
3/2/2018NomuraBoost Price TargetBuy$96.00HighView Rating Details
2/5/2018William BlairReiterated RatingOutperformHighView Rating Details
1/23/2018BarclaysReiterated RatingHold$55.00LowView Rating Details
1/3/2018Janney Montgomery ScottInitiated CoverageBuy -> Buy$75.00MediumView Rating Details
12/27/2017OppenheimerReiterated RatingBuy$76.00LowView Rating Details
12/27/2017UBSReiterated RatingOutperform$76.00 -> $56.51LowView Rating Details
10/27/2017Needham & Company LLCReiterated RatingBuyN/AView Rating Details
10/17/2017Robert W. BairdReiterated RatingBuy$101.00N/AView Rating Details
10/6/2017Goldman SachsReiterated RatingBuy -> Buy$71.00N/AView Rating Details
10/2/2017InstinetReiterated RatingBuy$84.00LowView Rating Details
9/14/2017CowenReiterated RatingOutperform$69.00MediumView Rating Details
4/6/2017Jefferies GroupReiterated RatingHold$27.00MediumView Rating Details
3/1/2017JMP SecuritiesLower Price Target$48.00N/AView Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00N/AView Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00N/AView Rating Details
5/5/2016Ladenburg ThalmannDowngradeMarket Perform -> Underperform$13.00 -> $5.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Sarepta Therapeutics (NASDAQ:SRPT) Earnings History and Estimates Chart

Earnings by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) Earnings Estimates

2018 EPS Consensus Estimate: ($1.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.45)($0.38)($0.40)
Q2 20183($0.42)($0.30)($0.35)
Q3 20183($0.31)($0.25)($0.28)
Q4 20183($0.19)($0.15)($0.16)

Sarepta Therapeutics (NASDAQ SRPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018($0.32)N/AView Earnings Details
4/25/2018($0.29)N/AView Earnings Details
3/1/2018Q4 2017($0.32)($0.37)$57.33 million$57.30 millionViewListenView Earnings Details
10/25/2017Q3 2017($0.86)($0.20)$41.29 million$45.95 millionViewN/AView Earnings Details
7/19/2017Q2 2017($0.92)($0.46)$22.52 million$35.01 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.85)($0.73)$13.80 million$16.34 millionViewN/AView Earnings Details
2/28/2017Q416($1.33)($0.71)$4.86 million$5.42 millionViewListenView Earnings Details
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.1920)($1.35)$1.10 millionViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.29)($0.24)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.42)($0.30)ViewN/AView Earnings Details
3/1/2012Q4 2011($0.36)($0.06)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.30)($0.18)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.42)$0.05ViewN/AView Earnings Details
5/5/2011Q1 2011($0.18)$0.12ViewN/AView Earnings Details
3/10/2011Q4 2010($0.42)($0.41)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.36)($0.42)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.30)($0.91)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.24)($0.03)ViewN/AView Earnings Details
3/16/2010Q4 2009($0.36)$0.18ViewN/AView Earnings Details
11/9/2009Q3 2009($0.42)($0.48)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.12)($0.36)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.18)($0.07)ViewN/AView Earnings Details
3/10/2009Q4 2008($0.30)($0.10)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.42)($0.50)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.42)($0.14)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.78)($0.47)ViewN/AView Earnings Details
3/12/2008Q4 2007($0.45)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sarepta Therapeutics (NASDAQ:SRPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sarepta Therapeutics (NASDAQ SRPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 84.94%
Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ SRPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2017Hans Lennart Rudolf WigzellDirectorSell6,667$55.89$372,618.6313,333View SEC Filing  
11/8/2017Douglas S IngramCEOBuy38,138$52.44$1,999,956.72420,196View SEC Filing  
11/6/2017Shamim RuffSVPSell10,000$55.00$550,000.0037,045View SEC Filing  
10/3/2017Shamim RuffSVPSell11,500$50.00$575,000.00View SEC Filing  
7/27/2017Douglas S IngramCEOBuy47,058$42.50$1,999,965.00382,058View SEC Filing  
7/21/2017Shamim RuffSVPSell12,138$42.97$521,569.8627,312View SEC Filing  
7/20/2017Alexander CumboSVPSell5,918$41.00$242,638.0022,793View SEC Filing  
7/20/2017Edward M Md KayeDirectorSell10,000$41.00$410,000.0062,471View SEC Filing  
7/20/2017Sandesh MahatmeCFOSell50,000$41.00$2,050,000.0041,736View SEC Filing  
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.0061,532View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.0028,453View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00117,162View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.0011,168View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.0089,983View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.0021,490View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.0076,983View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00112,166View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00112,166View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.0041,744View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.0044,166View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.0031,744View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.005,000View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sarepta Therapeutics (NASDAQ SRPT) News Headlines

Source:
DateHeadline
Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and ...Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and ...
globenewswire.com - April 24 at 8:07 AM
Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Devel-opments on May 3, 2018Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Devel-opments on May 3, 2018
finance.yahoo.com - April 23 at 5:23 PM
Sarepta Therapeutics (SRPT) Receives "Buy" Rating from HC WainwrightSarepta Therapeutics (SRPT) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - April 23 at 7:40 AM
A Look at Sarepta Therapeutics’ Cash FlowsA Look at Sarepta Therapeutics’ Cash Flows
finance.yahoo.com - April 21 at 5:25 PM
Exploring the Product Candidates of Sarepta TherapeuticsExploring the Product Candidates of Sarepta Therapeutics
finance.yahoo.com - April 21 at 8:06 AM
Analysts’ Ratings for Sarepta Therapeutics and Peers in AprilAnalysts’ Ratings for Sarepta Therapeutics and Peers in April
finance.yahoo.com - April 21 at 8:06 AM
SRPT July 20th Options Begin TradingSRPT July 20th Options Begin Trading
www.nasdaq.com - April 19 at 5:54 PM
Sarepta Therapeutics Inc (SRPT) Given Consensus Recommendation of "Buy" by BrokeragesSarepta Therapeutics Inc (SRPT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 18 at 1:34 PM
William Blair Comments on Sarepta Therapeutics Incs Q2 2018 Earnings (SRPT)William Blair Comments on Sarepta Therapeutics Inc's Q2 2018 Earnings (SRPT)
www.americanbankingnews.com - April 18 at 8:10 AM
How BTCY Could Look a Lot Like SRPT in a Years TimeHow BTCY Could Look a Lot Like SRPT in a Year's Time
finance.yahoo.com - April 18 at 8:03 AM
Sarepta Therapeutics (SRPT) Set to Announce Earnings on WednesdaySarepta Therapeutics (SRPT) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 18 at 4:38 AM
Pfizers DMD Drug Could Spell Long Term Trouble For SareptaPfizer's DMD Drug Could Spell Long Term Trouble For Sarepta
seekingalpha.com - April 17 at 8:06 AM
William Blair Weighs in on Sarepta Therapeutics Incs FY2020 Earnings (SRPT)William Blair Weighs in on Sarepta Therapeutics Inc's FY2020 Earnings (SRPT)
www.americanbankingnews.com - April 17 at 7:05 AM
Sarepta Therapeutics Inc (SRPT) Expected to Post Quarterly Sales of $64.82 MillionSarepta Therapeutics Inc (SRPT) Expected to Post Quarterly Sales of $64.82 Million
www.americanbankingnews.com - April 15 at 2:48 AM
Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to EqualweightMorgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight
www.streetinsider.com - April 14 at 8:06 AM
June 15th Options Now Available For Sarepta Therapeutics (SRPT)June 15th Options Now Available For Sarepta Therapeutics (SRPT)
www.nasdaq.com - April 13 at 5:47 PM
Sarepta Therapeutics Inc (SRPT) Expected to Announce Earnings of -$0.32 Per ShareSarepta Therapeutics Inc (SRPT) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - April 13 at 5:17 PM
Sarepta Therapeutics (SRPT) Stock Rating Upgraded by BidaskClubSarepta Therapeutics (SRPT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 13 at 9:39 AM
Notable Thursday Option Activity: RRR, BMY, SRPTNotable Thursday Option Activity: RRR, BMY, SRPT
www.nasdaq.com - April 12 at 5:56 PM
What Drove Sarepta Therapeutics Stock in March 2018?What Drove Sarepta Therapeutics Stock in March 2018?
finance.yahoo.com - April 9 at 5:35 PM
Sarepta Therapeutics (SRPT) Lifted to Overweight at Morgan StanleySarepta Therapeutics (SRPT) Lifted to Overweight at Morgan Stanley
www.americanbankingnews.com - April 8 at 3:17 PM
Sarepta Therapeutics (SRPT) "Buy" Rating Reiterated at Royal Bank of CanadaSarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM
ValuEngine Lowers Sarepta Therapeutics (SRPT) to SellValuEngine Lowers Sarepta Therapeutics (SRPT) to Sell
www.americanbankingnews.com - April 8 at 10:47 AM
Sarepta Hit With Call to Drop Duchenne Drug CostsSarepta Hit With Call to Drop Duchenne Drug Costs
finance.yahoo.com - April 6 at 5:54 PM
Credit Suisse Group Reiterates $100.00 Price Target for Sarepta Therapeutics (SRPT)Credit Suisse Group Reiterates $100.00 Price Target for Sarepta Therapeutics (SRPT)
www.americanbankingnews.com - April 6 at 11:07 AM
Piper Jaffray Reiterates "Overweight" Rating for Sarepta Therapeutics (SRPT)Piper Jaffray Reiterates "Overweight" Rating for Sarepta Therapeutics (SRPT)
www.americanbankingnews.com - April 4 at 8:34 PM
Sarepta Therapeutics (SRPT) Upgraded by ValuEngine to BuySarepta Therapeutics (SRPT) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - April 3 at 12:00 AM
Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?
finance.yahoo.com - April 2 at 8:06 AM
3 Hot Biotech Stocks Facing Sharp Declines3 Hot Biotech Stocks Facing Sharp Declines
finance.yahoo.com - April 2 at 8:06 AM
HC Wainwright Reiterates "$75.00" Price Target for Sarepta Therapeutics (SRPT)HC Wainwright Reiterates "$75.00" Price Target for Sarepta Therapeutics (SRPT)
www.americanbankingnews.com - March 30 at 11:43 PM
Sarepta Therapeutics (SRPT) Cut to Buy at BidaskClubSarepta Therapeutics (SRPT) Cut to Buy at BidaskClub
www.americanbankingnews.com - March 29 at 9:15 AM
Investors sue Solid Biosciences, say they were duped about Duchenne drug’s safetyInvestors sue Solid Biosciences, say they were duped about Duchenne drug’s safety
finance.yahoo.com - March 28 at 5:32 PM
-$0.32 EPS Expected for Sarepta Therapeutics Inc (SRPT) This Quarter-$0.32 EPS Expected for Sarepta Therapeutics Inc (SRPT) This Quarter
www.americanbankingnews.com - March 27 at 7:20 PM
Sarepta Therapeutics (SRPT) Now Covered by Analysts at Royal Bank of CanadaSarepta Therapeutics (SRPT) Now Covered by Analysts at Royal Bank of Canada
www.americanbankingnews.com - March 27 at 12:41 AM
Sarepta Therapeutics Inc (SRPT) Receives Average Recommendation of "Buy" from BrokeragesSarepta Therapeutics Inc (SRPT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 24 at 1:38 PM
Sarepta Therapeutics (SRPT) Downgraded by Morgan StanleySarepta Therapeutics (SRPT) Downgraded by Morgan Stanley
www.americanbankingnews.com - March 21 at 6:40 PM
Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program - GlobeNewswire (press release)Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program - GlobeNewswire (press release)
globenewswire.com - March 21 at 8:19 AM
Edited Transcript of SRPT earnings conference call or presentation 1-Mar-18 9:30pm GMTEdited Transcript of SRPT earnings conference call or presentation 1-Mar-18 9:30pm GMT
finance.yahoo.com - March 21 at 8:19 AM
Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship ProgramSarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
finance.yahoo.com - March 20 at 5:28 PM
Credit Suisse Group Boosts Sarepta Therapeutics (SRPT) Price Target to $100.00Credit Suisse Group Boosts Sarepta Therapeutics (SRPT) Price Target to $100.00
www.americanbankingnews.com - March 18 at 11:32 AM
Sarepta Therapeutics (SRPT) Raised to "Strong-Buy" at BidaskClubSarepta Therapeutics (SRPT) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 17 at 4:28 PM
Sarepta Therapeutics (SRPT) PT Raised to $95.00 at SunTrust BanksSarepta Therapeutics (SRPT) PT Raised to $95.00 at SunTrust Banks
www.americanbankingnews.com - March 16 at 6:06 PM
Solid Biosciences Pain Is Sareptas GainSolid Biosciences' Pain Is Sarepta's Gain
finance.yahoo.com - March 15 at 6:29 PM
Sarepta Buoyed As Rival Craters On Muscular Dystrophy Drug RulingSarepta Buoyed As Rival Craters On Muscular Dystrophy Drug Ruling
finance.yahoo.com - March 15 at 6:29 PM
Leerink Swann Research Analysts Raise Earnings Estimates for Sarepta Therapeutics Inc (SRPT)Leerink Swann Research Analysts Raise Earnings Estimates for Sarepta Therapeutics Inc (SRPT)
www.americanbankingnews.com - March 15 at 12:26 PM
Royal Bank of Canada Reaffirms Buy Rating for Sarepta Therapeutics (SRPT)Royal Bank of Canada Reaffirms Buy Rating for Sarepta Therapeutics (SRPT)
www.americanbankingnews.com - March 14 at 9:40 PM
Shares of Solid Biosciences crater as FDA halts Duchenne gene therapy trialShares of Solid Biosciences crater as FDA halts Duchenne gene therapy trial
finance.yahoo.com - March 14 at 7:25 PM
JPMorgan Chase & Co. Raises Sarepta Therapeutics (SRPT) Price Target to $95.00JPMorgan Chase & Co. Raises Sarepta Therapeutics (SRPT) Price Target to $95.00
www.americanbankingnews.com - March 14 at 10:52 AM
Sarepta Therapeutics (SRPT) Positive Rating Reaffirmed at Leerink SwannSarepta Therapeutics' (SRPT) Positive Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - March 13 at 1:39 PM
Sarepta Therapeutics plans NDA of Duchenne MD treatment by year end - MarketWatchSarepta Therapeutics plans NDA of Duchenne MD treatment by year end - MarketWatch
www.marketwatch.com - March 13 at 8:05 AM

SEC Filings

Sarepta Therapeutics (NASDAQ:SRPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sarepta Therapeutics (NASDAQ:SRPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sarepta Therapeutics (NASDAQ SRPT) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.